MedClone Inc. said that preliminary Phase I clinical trial results onMAb 3E10, a vaccine for the treatment of nephritis associated withsystemic lupus erythematosus (SLE), have shown that the majority ofthe response was anti-idiotypic.Six patients completed the injection phase of the study in the lowestdosage arm. Four of the five patients randomized to MAb 3E10completed the full treatment cycle of six injections; the fifth becamehuman anti-murine antibody (HAMA) positive (by ELISA) after thefourth injection.A positive weaker anti-idiotypic response was detected without asubstantial HAMA response in the remaining four MAb 3E10 patients.In one patient, a concomitant reduction in anti-double-stranded DNAantibody levels was seen, while another patient exhibited a progressivereduction in serum creatinine levels. No adverse events were reported.
(c) 1997 American Health Consultants. All rights reserved.